reports
Milestone® Pharmaceuticals to Present Data on Etripamil at the Prevent...
Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium MONTREAL and CHARLOTTE, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will present data on etripamil at the 30th Annual Cardiovascular Nursing Symposium held by the Preventive Cardiovascular Nurses Association on April 18-20th in Orlando, FL. The posters will be available following the embargo at . ...
Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Pati...
Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients’ Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting Data from this large safety-trial also published in The Journal of the American College of Cardiology MONTREAL and CHARLOTTE, N.C., April 08, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced new clinical data demonstrating real-world application of etripamil,...
Milestone® Pharmaceuticals to Present at the 23rd Annual Needham Healt...
Milestone® Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference MONTREAL and CHARLOTTE, N.C., April 03, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will deliver a company presentation at the 23rd Annual Needham Virtual Healthcare Conference on April 10, 2024 at 8:45 am ET. The webcast is available to watch both live and replay for approximately 90 days following the presentation in the News & Events section of Milestone’s website. About Milestone PharmaceuticalsMilestone Pharmaceu...
Milestone® Pharmaceuticals to Present Data on Etripamil at the America...
Milestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences MONTREAL and CHARLOTTE, N.C., April 01, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will present data on etripamil at two upcoming cardiology conferences this month. The company will deliver oral and poster presentations at the , to be held April 6-8th in Atlanta, Georgia, a...
Milestone Pharmaceuticals Announces Resubmission of New Drug Applicati...
Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia MONTREAL and CHARLOTTE, N.C., March 28, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the resubmission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for etripamil, the Company’s lead investigational product for the management of paroxysmal supraventricular...
- Jonathan Moreland
TTSH TILE SHOP HOLDINGS INC.
OPK OPKO HEALTH INC.
NYCB NEW YORK COMMUNITY BANCORP INC.
MHLD MAIDEN HOLDINGS LTD.
GOGO GOGO INC.
DLTR DOLLAR TREE INC.
CTRN CITI TRENDS INC.
CRMT AMERICA'S CAR-MART INC.
HRTG HERITAGE INSURANCE HOLDINGS INC.
AAOI APPLIED OPTOELECTRONICS INC.
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
NXJ NUVEEN NEW JERSEY DIVIDEND ADVANTAGE MUNICIPAL FUND
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
VICI VICI PROPERTIES INC
CDLX CARDLYTICS INC
TALO TALOS ENERGY INC.
STKS THE ONE GROUP HOSPITALITY INC.
PAYS PAYSIGN INC
REEMF RARE ELEMENT RESOURCES
DCTH DELCATH SYSTEMS
RZLT REZOLUTE
MYO INC.
XERS MYOMO
LEE XERIS BIOPHARMA HLDGS INC
QSI LEE ENTERPRISES INC
ASLE QUANTUM-SI INC
VPV AERSALE CORP
BPRN INVESCO PA VALUE MUNI INC TST
CYT BANK OF PRINCETON
CYTEIR THERAPEUTICS INC
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Fi...
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update - On track to resubmit NDA for etripamil in PSVT early 2Q 2024 - Recent financing extends cash runway into 2026 - FDA reiterated prior guidance on regulatory pathway for AFib-RVR, End of Phase 2 Meeting expected mid-2024 MONTREAL and CHARLOTTE, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the fourth quarter and year ended December 31, 2023 and provided a regulatory and corporate...
Opko Health Inc: 1 director
A director at Opko Health Inc bought 500,000 shares at 0.874USD and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
- Jonathan Moreland
GOGO GOGO INC.
DLTR DOLLAR TREE INC.
HRTG HERITAGE INSURANCE HOLDINGS INC.
AAOI APPLIED OPTOELECTRONICS INC.
VICI VICI PROPERTIES INC
CDLX CARDLYTICS INC
CSPI CSP INC.
PAYS PAYSIGN INC
HRMY HARMONY BIOSCIENCES HOLDINGS
MYO MYOMO
CLOV CLOVER HEALTH INV CORP
IMRX IMMUNEERING CORP
XERS XERIS BIOPHARMA HLDGS INC
SPRB SPRUCE BIOSCIENCES INC
QSI QUANTUM-SI INC
ASLE AERSALE CORP
BPRN BANK OF PRINCETON
- Jonathan Moreland
TLYS TILLYS
SSNC SS&C TECHNOLOGIES HOLDINGS INC.
OPK OPKO HEALTH INC.
HOO HERBALIFE NUTRITION LTD.
CTRN CITI TRENDS INC.
CE CELANESE CORPORATION
BANC BANC OF CALIFORNIA INCORPORATED
HWBK HAWTHORN BANCSHARES
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
JFR NUVEEN FLOATING RATE INCOME FUND
NXJ NUVEEN NEW JERSEY DIVIDEND ADVANTAGE MUNICIPAL FUND
AYX ALTERYX
FMN FEDERATED PREMIER MUNICIPAL INCOME FUND
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
QNBC QNB CORP.
TALO TALOS ENERGY INC.
RBB RBB BANCORP
AXR AMREP
SKYE NEMUS BIOSCIENCE INC
ELAN ELANCO ANIMAL HEALTH INC.
ANIX ANIXA BIOSCIENCES
PAYS PAYSIGN INC
KSM DWS STRATEGIC MUNICIPAL INCOME TRUST
VTN INVESCO TRUST FOR INVESTMENT G
RZLT REZOLUTE
COOK INC.
MPA TRAEGER
FRST INC.
ASLE BLACKROCK MUNIYIELD PENNSYLVANIA FD
VPV PRIMIS FINANCIAL CORP
BPRN AERSALE CORP
CRBP INVESCO PA VALUE MUNI INC TST
LSXMK BANK OF PRINCETON
BHRB CORBUS PHARMACEUTICALS HOLDINGS INC.
MDRX LIBERTY SIRIUSXM GROUP
APRE BURKE HERBERT FINANCIAL SERVICES CORP
ALLSCRIPTS-MISYS HEALTHCARE SOLUTIONS
INC.
APREA THERAPEUTICS INC
- Jonathan Moreland
- Jonathan Moreland
OPK OPKO HEALTH INC.
HOO HERBALIFE NUTRITION LTD.
CTRN CITI TRENDS INC.
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
NXJ NUVEEN NEW JERSEY DIVIDEND ADVANTAGE MUNICIPAL FUND
FMN FEDERATED PREMIER MUNICIPAL INCOME FUND
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
QNBC QNB CORP.
ELAN ELANCO ANIMAL HEALTH INC.
ZM ZOOM VIDEO COMMUNICATIONS
KSM INC.
VTN DWS STRATEGIC MUNICIPAL INCOME TRUST
MPA INVESCO TRUST FOR INVESTMENT G
VPV BLACKROCK MUNIYIELD PENNSYLVANIA FD
LSXMK INVESCO PA VALUE MUNI INC TST
LIBERTY SIRIUSXM GROUP
AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX...
AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV • Study delivers first clinical safety and pharmacokinetic data as proof of concept for the use of multispecific antibodies in humans• Candidate showed similar half-life to standard monoclonal antibodies and minimal anti-drug antibodies WESTON, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced results from a Phase 1 clinical study of SAR441236, its trispecific broadly neutralizing ant...
Milestone® Pharmaceuticals to Participate in a Corporate Panel Discuss...
Milestone® Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference MONTREAL and CHARLOTTE, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will participate in a corporate panel discussion at the TD Cowen 44th Annual Health Care Conference on March 5, 2024, at 10:30am ET. The webcast is available to watch both live and replay for approximately 90 days following the presentation in the News & Events section of Milestone's website. About Mileston...
Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Of...
Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants MONTREAL and CHARLOTTE, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the pricing of its previously announced underwritten public offering (the “Offering”) of (i) 16,666,667 of its common shares (the “Shares”) at a public offering price of $1.50 per share and (ii) in lieu of common share...
- Jonathan Moreland
Milestone Pharmaceuticals Announces Proposed Public Offering of Common...
Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants MONTREAL and CHARLOTTE, N.C., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it has commenced an underwritten public offering (the “Offering”) of its common shares (the “Shares,”), and, in lieu of common shares to certain investors that so choose, pre-funded warrants to purchase common shares (“Pre-Funded...
OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financ...
OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI, Feb. 27, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2023. Business highlights from the fourth quarter and subsequent weeks included the following: ModeX advanced its antiviral and immune-oncology product pipeline. ModeX advanced its pipeline of antiviral and immune-oncology programs utilizing its next-generation multispecific antibodi...
Milestone Pharmaceuticals Announces Plan to Resubmit NDA for Etripamil...
Milestone Pharmaceuticals Announces Plan to Resubmit NDA for Etripamil for the Treatment of PSVT Resubmission of NDA expected 2Q2024 Operating Runway Extended Into Mid-2025 with Cash Conservation Measures MONTREAL and CHARLOTTE, N.C., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced plans to resubmit the New Drug Application (NDA) for etripamil to the U.S. Food and Drug Administration (FDA) for paroxysmal supraventricular tachycardia (PSVT). Following the previously announced receipt of a , Milestone held a Type A Meeting with FDA. ...
OPKO Health to Report Fourth Quarter 2023 Financial Results on Februar...
OPKO Health to Report Fourth Quarter 2023 Financial Results on February 27, 2024 MIAMI, Feb. 22, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and 12 months ended December 31, 2023 after the close of the U.S. financial markets on Tuesday, February 27, 2024. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on February 27th beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.